CBO hints that Medicare may soon cov­er obe­si­ty drugs for their car­dio­vas­cu­lar ben­e­fits

Medicare is star­ing down tens of bil­lions of dol­lars in fu­ture ex­pens­es if it be­gins cov­er­ing obe­si­ty drugs like No­vo Nordisk’s We­govy and Eli Lil­ly’s Zep­bound, and the Con­gres­sion­al Bud­get Of­fice has sug­gest­ed that may be soon, thanks to the heart ben­e­fits seen in pa­tients tak­ing We­govy.

In writ­ten ques­tions, Rep. Bud­dy Carter (R-GA) asked the CBO how it is con­sid­er­ing the costs of GLP-1s like We­govy and Zep­bound now that the FDA ex­pand­ed the la­bel for No­vo’s drug to in­clude car­dio­vas­cu­lar risk re­duc­tion ben­e­fits.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER